The global escitalopram market is anticipated to grow at a significant CAGR of nearly 3.0% during the forecast period (2022-2028). The major factor expected to drive the market is the rising prevalence of major depressive disorder across the globe and the availability of low-cost generic versions of escitalopram drive the market growth. In addition, the effective implementation of treatment guidelines about mental health will further boost the growth of the global escitalopram market during the forecast period. Moreover, after availability of generic drug, there has been a significant reduction in its cost and hence it is frequently prescribed by psychiatrists throughout the globe which will further support the market growth.
Escitalopram comes under the brand names of Lexapro and Cipralex is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is a drug used to treat depression and certain anxiety disorders. In addition, it may also be useful when prescribed “off-label” (without approval by Food and Drug Administration (FDA)) for the obsessive-compulsive disorder (OCD), eating disorders such as panic disorder, posttraumatic stress disorder (PTSD), binge eating disorder or bulimia nervosa, and premenstrual dysphoric disorder (PMDD). Additionally, the funded brand of escitalopram changed to the Ethics-Escitalopram brand from the Apo-Escitalopram brand, and from 1 October 2021 only the Ethics-Escitalopram brand of escitalopram is fully funded. Furthermore, the rise in the incidences of mental health disorders, the growing geriatric population, and the rise in the demand for antidepressants will boost the growth of the escitalopram market during the forecast period. Some major players in the market include Mylan NV, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.
(Get 15% Discount on Buying this Report)
Get Sample Copy of global escitalopram market at:
https://orionmarketreports.com/request-sample/?id=95565&submit=Request+Sample%0D%0A
Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Product Type
By Indication
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World
Top Major Key Players:
Mylan NV, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd., among others.
Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?
A full report of global escitalopram market is available at:
https://orionmarketreports.com/global-escitalopram-market/95565/
Global Escitalopram Market Report by Segment
By Product Type
Solution
Tablet
By Indication
Major Depressive Disorder
Generalized Anxiety Disorder
Obsessive Compulsive Disorder
Post-Traumatic Stress Disorder
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
